VCELVericel Corp
Biological Products, (no Diagnostic Substances)
- Revenue
- $276M
- 16% YoY
- Operating margin
- 4.0%
- 110% YoY
- EBITDA
- $23M
- 125% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -5.0×
- −$112M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear314% of net incomeCash flow under 80% of net income
- Dilutive SBCFired14% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $153M | $164M | $198M | $237M | $276M | 16% |
| Operating income | −$8M | −$17M | −$6M | $5M | $11M | 144% |
| Net income | −$7M | −$17M | −$3M | $10M | $17M | 59% |
| Operating cash flow | $29M | $18M | $35M | $58M | $52M | 11% |
| Capex | $8M | $8M | $20M | $64M | $27M | 58% |
| Stock-based comp | $34M | $37M | $32M | $36M | $39M | 6.2% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.